Innovation Fund Denmark   Report issue

Foundation Phase 1 Phase 3 Phase 4
Founded: Aarhus Denmark (2014)

Organization Overview

First Clinical Trial
2016
NCT02829697
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Innovation Fund Denmark

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis, Infectious (Phase 4)

Communicable Diseases (Phase 4)

Infections (Phase 4)

Osteomyelitis (Phase 4)

Pain, Postoperative (Phase 4)

Shock (Phase 3)

Shock, Septic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 12